Raynaud's phenomenon, scleroderma, overlap syndromes, and other fibrosing syndromes

Current Opinion in Rheumatology

Volumn 12, Issue 6, 2000, Pages 509-510

  Korn, Joseph H ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTACYCLIN; RELAXIN;

AUTOIMMUNE DISEASE; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; FIBROSIS; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PATHOGENESIS; PREGNANCY; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; RISK FACTOR; SEX DIFFERENCE; STEM CELL TRANSPLANTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

HUMANS; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; SYNDROME;

EID: 0033753184     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200011000-00006     Document Type: Review

References (10)

1. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma: Association with Amerindian HLA haplotype
2. Association of microsatellite markers near the fibrillin 1 gene on human chromosome 15q with scleroderma in a Native American population
3. 1,1'-Ethylidenebis [L-tryptophan], an impurity in L-tryptophan associated with eosinophilia-myalgia syndrome, stimulate type I collagen gene expression in human fibroblasts in vitro
4. Current knowledge about fetal blood cells in the maternal circulation
5. Fetal-maternal HLA compatibility confers susceptibility to systemic sclerosis
6. Microchimerism of maternal origin persists into adult life
7. Epidemiologic and clinical study of twins with scleroderma
8. Recombinant human relaxin in the treatment of scleroderma: A randomized, double-blind, placebo-controlled trial
9. Systemic sclerosis-associated pulmonary hypertension: Short- and long-term effects of epoprostenol (prostacyclin)
10. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: A randomized, controlled trial